[go: up one dir, main page]

WO2005079767A3 - Means for modulation of the effects of opioid-like substances - Google Patents

Means for modulation of the effects of opioid-like substances Download PDF

Info

Publication number
WO2005079767A3
WO2005079767A3 PCT/EP2005/000102 EP2005000102W WO2005079767A3 WO 2005079767 A3 WO2005079767 A3 WO 2005079767A3 EP 2005000102 W EP2005000102 W EP 2005000102W WO 2005079767 A3 WO2005079767 A3 WO 2005079767A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
modulation
substances
effects
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/000102
Other languages
French (fr)
Other versions
WO2005079767A2 (en
Inventor
Thomas Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Muenster
Original Assignee
Universitaetsklinikum Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Muenster filed Critical Universitaetsklinikum Muenster
Publication of WO2005079767A2 publication Critical patent/WO2005079767A2/en
Publication of WO2005079767A3 publication Critical patent/WO2005079767A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of an opiate-receptor antagonist for the preparation of a pharmaceutical composition for treating or preventing heart failure in a human subject or multi-organ dysfunction syndrome in a subject. The invention also relates to a method for treating a human subject suffering from heart failure or multi-organ dysfunction syndrome comprising the step of administering to said subject an opiate-receptor antagonist in a thera­peutically effective dosage.
PCT/EP2005/000102 2004-02-19 2005-01-07 Means for modulation of the effects of opioid-like substances Ceased WO2005079767A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003708.7 2004-02-19
EP04003708 2004-02-19

Publications (2)

Publication Number Publication Date
WO2005079767A2 WO2005079767A2 (en) 2005-09-01
WO2005079767A3 true WO2005079767A3 (en) 2005-12-01

Family

ID=34878161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000102 Ceased WO2005079767A2 (en) 2004-02-19 2005-01-07 Means for modulation of the effects of opioid-like substances

Country Status (1)

Country Link
WO (1) WO2005079767A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COTTE NATHALIE ET AL: "Prevention and rescue of a mouse model of dilated cardiomyopathy targeting the hyperactive signaling of a Gi-coupled receptor", CIRCULATION, vol. 104, no. 17 Supplement, 23 October 2001 (2001-10-23), & SCIENTIFIC SESSIONS 2001 OF THE AMERICAN HEART ASSOCIATION; ANAHEIM, CALIFORNIA, USA; NOVEMBER 11-14, 2001, pages II.367, XP009053469, ISSN: 0009-7322 *
HIMURA YOSHIHIRO ET AL: "Short-term effects of naloxone on hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 23, no. 1, 1994, pages 194 - 200, XP009053395, ISSN: 0735-1097 *
IMAI NAOAKI ET AL: "Comparison of cardiovascular effect of mu- and delta-opioid receptor antagonists in dogs with congestive heart failure", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 267, no. 3 PART 2, 1994, pages H912 - H917, XP009053467, ISSN: 0002-9513 *
KINDMAN L A ET AL: "OPIOIDS POTENTIATE CONTRACTILE RESPONSE OF RABBIT MYOCARDIUM TO THE BETA ADRENERGIC AGONIST ISOPROTERENOL", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 17, no. 1, 1991, pages 61 - 67, XP009053424, ISSN: 0160-2446 *
LIANG C-S ET AL: "THE ROLE OF ENDOGENOUS OPIOIDS IN CONGESTIVE HEART FAILURE EFFECTS OF NALMEFENE ON SYSTEMIC AND REGIONAL HEMODYNAMICS IN DOGS", CIRCULATION, vol. 75, no. 2, 1987, pages 443 - 451, XP002344142, ISSN: 0009-7322 *
LLOBEL F ET AL: "Effects of mu-, delta, and kappa-opioid antagonists in atrial preparations from nonfailing and failing human hearts", GENERAL PHARMACOLOGY, vol. 28, no. 3, 1997, pages 371 - 374, XP002344141, ISSN: 0306-3623 *
OLDROYD K G ET AL: "Activation and inhibition of the endogenous opioid system in human heart failure", BRITISH HEART JOURNAL, vol. 73, no. 1, 1995, pages 41 - 48, XP009053439, ISSN: 0007-0769 *

Also Published As

Publication number Publication date
WO2005079767A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2004073614A3 (en) Combination therapy for the treatment of immunoinflammatory disorders
WO2004050020A3 (en) Improved opioid pharmaceutical compositions
EP1933833B8 (en) Therapy for the treatment of overactive bladder
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2001054706A3 (en) Method for treating kidney disorders
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2005004854A3 (en) Use of betaine for treating arteritis
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2007038506A3 (en) Method for the treatment of cachexia
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2005079767A3 (en) Means for modulation of the effects of opioid-like substances
WO2005091987A3 (en) Method of treating down syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2005 UNDER (81) ADD "SM"

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase